What’s Happening With RXRX Stock?

RXRX remains down by 35% year-to-date and is trading below $5. Thus, the critical question isn’t about a single good ...

Recursion jumps as J.P. Morgan upgrades on lead program

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) a…

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...